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Protein citrullination is emerging as an important signaling mechanism that modulates a
variety of biological processes. This protein modification constitutes only a 1 Da mass shift,
and can be readily confused with other common protein modifications that yield an identical
mass shift. In an attempt to develop a robust methodology for detection of protein citrullina-
tion sites, we analyzed synthetic citrulline-containing peptides by electrospray ionization
tandem mass spectrometry. Collision-induced dissociation (CID) spectra revealed abundant
neutral loss of 43 Da from citrullinated peptide precursor ions, which was reconciled by
elimination of the HNCO moiety (isocyanic acid) from the citrulline ureido group. The
elimination occurs readily in multiple charge states of precursor ions and also in b and y ions.
HNCO loss in CID spectra provides a novel diagnostic marker for citrullination, and its utility
was demonstrated by the discovery of Arg197 as the specific site of citrullination on
nucleophosmin upon peptidylarginine deiminase 4 treatment. (J Am Soc Mass Spectrom
2009, 20, 723–727) © 2009 American Society for Mass SpectrometryCitrullination is a post-translational modificationin mammalian cells through which peptidyl-arginine residues are converted to citrullines
(Cit), catalyzed by the peptidylarginine deiminase (PAD)
family of enzymes [1, 2]. This modification removes the
positive charge on arginine (a process termed deimida-
tion), abolishing intra- and intermolecular electrostatic
interactions that can modulate the structure and function
of proteins. Citrullination is involved in diverse cellular
processes including gene regulation, apoptosis, and skin
homeostasis [3–5]. Alteration in the level of citrullination
is implicated in the pathogenesis of disorders such as
multiple sclerosis, rheumatoid arthritis (RA), psoriasis,
and Alzheimer’s disease [6–9]. In RA, it has been shown
that elevated protein citrullination in synovial joints trig-
gers an autoimmune response and results in damage to
the joints [10, 11]. An assay foranti-citrullinated peptide
IgG is highly specific for RA in patients and widely used
for clinical diagnosis of RA [12, 13].
Notwithstanding the apparent biologic importance
of protein citrullination, less than a dozen in vivo
citrullinated proteins have been identified, including
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doi:10.1016/j.jasms.2008.12.012histone proteins (H3, H2A, H4), nucleophosmin, mye-
lin, and keratin [14–19]. While anti-citrulline antibodies
can sensitively detect protein citrullination, definition
of the exact site of modification can only be established
via mass spectrometric approaches. A problem is that
the mass shift resulted from conversion of peptidyl
arginine to Cit is small (1 Da) and isobaric with
deamidation on Asn and Gln residues, making it chal-
lenging for mass spectrometric detection, especially on
low-resolution mass spectrometry instrumentations. A
common strategy to enhance confidence in the assign-
ment of a given post-translational modification is to
look for hallmark peptide fragmentation products in
MS/MS spectra, e.g., phosphate loss from phosphory-
lated serine or threonine [20, 21]. Recently, tandem
mass spectrometry studies of mono- and dimethyl-
arginine containing peptides revealed characteristic
neutral losses including monomethylamine, dimethyl-
carbodiimide, and dimethylamine from the modified
arginine side chain [22–24]. In the present study, we
explored the gas-phase fragmentation pathways of cit-
rullinated peptides by electrospray-tandem mass spec-
trometry and discovered a characteristic neutral loss of
43 Da that is reconciled by the release of an isocyanic
acid (HNCO) moiety from the citrulline ureido group.
The dependence of the elimination reaction on precur-
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that the neutral loss of HNCO can provide a specific
marker for identification of novel citrullinated proteins.
Experimental
Materials
Citrullinated reference peptides standard, including NH2-
AA{Cit}AA-COOH, NH2-AARAA-COOH, histone H4
peptide (residues 15–26) NH2-AK{Cit}H{Cit}KVL{Cit}DNI-
cysteine-COOH, and human NPM peptide (residues
195–202) NH2-SIRDTPAK-COOH were synthesized by
Genemed Syn. (San Francisco, CA). Recombinant hu-
man His6-nucleophosmin (His6-NPM) and glutathione-
S-transferase tagged peptidylarginine deiminase 4
(GST-PAD4) were recombinantly-expressed and puri-
fied from E. coli strain BL-21. Sequencing grade trypsin
was from Promega (Madison, WI). -Mod-Cit antibody
was from Millipore (Billerica, MA). All other reagents
were from Sigma-Aldrich (St. Louis, MO).
Mass Spectrometry
ESI mass spectra were recorded on a Q-Trap triple-
quadrupole linear ion trap mass spectrometer (Applied
Biosystems, Foster City, CA). Reference peptides were
diluted to final concentrations of 1 pmol/L in 50%
acetonitrile (ACN)/0.1% formic acid (FA) and directly
infused to a micro ion spray source at a flow rate of 5
L/min. All mass spectra were acquired in positive
ion mode. The spray voltage was 3800 V, the nebulizing
gas was 10, the curtain gas was 10, the source temper-
ature was 150 °C, and the declustering voltage was 50
V. CID spectra were acquired in enhanced product-ion
mode, at a scan rate of 4000 u/s. Twenty mass spectra
were averaged to achieve good ion statistics. The collision
energy (CE) was optimized to generate a modest level of
fragmentation, i.e., 25 V for AA{Cit}AA and AARAA
peptides and 45 V for AK{Cit}H{Cit}KVL{Cit}DNIC,
regardless of charge states. MS3 analysis of AA{Cit}AA
neutral loss ion was carried out with an activation time
of 100 ms and an excitation energy of 100 V. The LC-MS
analysis of a tryptic digest of nucleophosmin was
performed on a homemade capillary flow LC system
coupled to the Q Trap mass spectrometer via the micro
ion spray interface. All peptides were resolved on a
ZORBAX C18 (Agilent Technologies, Santa Clara, CA,
USA) 50  300 mm column at a mobile phase flow rate
of 4 L/min. The peptides were eluted using a two-
Scheme 1. Proposed fragmentation mechani
peptides.solvent gradient system, where Solvent A comprised
water in 0.1% FA and Solvent B was ACN in 0.1% FA.
The percentage of Solvent B was increased from 5% to
50% in 50 min and to 80% from 50 to 60 min. Data
dependent CID spectra were acquired on the two most
intense precursor ions after each MS scan. The CE value
used in the data-dependant acquisition was calculated by
the Analyst software using a charge state and m/z depen-
dent equation. The CE was 42 V for the singly-charged
peptide SI{R/Cit}DTPAK and 28 V for the doubly-
charged peptide. The CID spectra were searched against
the human NPM sequence using the ProteinPilot pro-
gram (version 2.01, Applied Biosystems) for peptide
identification.
Results and Discussion
We first studied a small citrullinated peptide, AA{Cit}AA,
and compared its fragmentation behavior with the
Arg-containing counterpart, AARAA. The resulting
CID spectra are shown in Supplemental Figure 1, which
can be found in the electronic version of this article.
Both peptides were found to be singly-protonated in
positive mode ESI. The observed m/z values were
consistent with mass increase resulted from deimida-
tion (460.3 for AA{Cit}AA and 459.3 for AARAA). A
modest level of collision energy (CE, 25V) was applied
and to leave a significant fraction of the precursor ion
intact. During the optimization process, a range of CE
was used and the resulting CID spectra were similar to
those shown in Supplemental Figure 1 with only quan-
titative differences. For the citrullinated peptide, in
addition to backbone cleavage products (b and y ions),
several neutral loss ions were observed adjacent to the
precursor ion. These include 17 Da, corresponding to
the loss of ammonia, and another peak at 43 Da,
whose identity was unpredicted. Upon inspection of the
Cit structure, the identity of the43 Da neutral loss was
considered to be a carbamyl group, or isocyanic acid
(HNCO), a stable compound with boiling point of
23.5 °C [25, 26]. The identity of the neutral loss species
was subsequently confirmed by probing the structure of
the43 Da peak: an ornithine residue (Orn) is expected
to be the product after loss of carbamyl group and MS3
analysis of the 43 ion showed that the other product
was indeed AA{Orn}AA (Supplemental Figure 1 inset).
HNCO loss also occurred on b3 and b4 ions, confirm-
ing the modification site. In contrast with fragmentation
spectra from AA{Cit}AA, only NH3 loss from AARAA
or isocyanic acid elimination from citrullinesm f
725J Am Soc Mass Spectrom 2009, 20, 723–727 NEUTRAL LOSS OF ISOCYANIC ACID IN PEPTIDE CIDFigure 1. Identification of citrullination site in PAD-4 treated human nucleophosmin (NPM). Protein
bands were in-gel digested with trypsin and resulting peptides were analyzed by LC-MS. Data-
dependant MS/MS scans were performed on the two most intense ions in each MS scan. The CID
spectra were searched for neutral loss of 43 and 21.5 Da. A single peptide ion, corresponding to
SI{Cit}DTPAK containing Arg197 was found in PAD4-treated band. The observed m/z was 888.4 for
the singly-charged peptide ion and 444.7 for the doubly-charged species. The CE used for the peptide
fragmentation was calculated using Analyst software (42 and 28 for singly- and doubly-charged ions,
respectively.) (a) Total ion chromatograms (TIC) of PAD4-treated and untreated human NPM. The
CID spectra were extracted to generate neutral loss spectra of 43 and 21.5 Da. Shown here is the 43 Da
neutral loss chromatogram that reveals a singly charged peptide SI{Cit}DTPAK eluted around 12 min
in the PAD4-treated sample. The neutral loss chromatogram of 21.5 Da similarly identified the doubly
charged precursor of the same citrullinated peptide (not shown). (b) and (c) CID spectra of the
citrullinated peptide SI{Cit}DTPAK and the native peptide SIRDTPAK. HNCO loss was abundant in
CID spectra of both the singly and doubly charged citrullinated peptide ions, whereas only ammonia
loss was found in the unmodified peptide spectra.
726 HAO ET AL. J Am Soc Mass Spectrom 2009, 20, 723–727was detected. The backbone fragmentation was also less
prominent in AARAA as compared with AA{Cit}AA,
attributed to proton sequestering by the Arg residue in
the former sequence.
A likely fragmentation mechanism for HNCO loss
is depicted in Scheme 1. The reaction is proposed to
proceed via two sequential steps. During the first step,
protonation at the  nitrogen of the citrulline side-chain
induced C–N bond fragmentation to initially yield an
ion molecule complex between ornithine and [OCNH2]
.
In the second step, proton transfer within the ion
molecule complex before its dissociation would then
yield the protonated ornithine containing product ion
and an isocyanic acid moiety.
To further investigate the fragmentation mechanism, a
human histone H4 peptide (residues 15–26 containing Cit
at positions 17, 19, and 23) AK{Cit}H{Cit}KVL{Cit}DNIC
was selected as a model peptide. Notably, citrullination
on histone proteins H3 and H4 is known to regulate
their DNA-binding properties and mediate chromo-
some assembly [3, 14]. The peptide carries an extra
C-terminal cysteine residue for the purpose of carrier
protein conjugation for antibody production. The syn-
thetic H4 peptide exist in three charge states, (1, 2,
and3), with molecular ions atm/z of 1611.8, 806.4, and
538.0 for singly-, doubly- and triply-charged peptides,
respectively. The CID spectra at CE of 45 V were shown
in Supplement Figure 2. The singly-protonated peptide
yielded predominantly a loss of NH3, HNCO, two
HNCO, and combined losses of NH3 and HNCO,
consistent with multiple citrullination sites in the se-
quence. Minimum backbone cleavage was observed, in
accord with the absence of a mobile proton in the
sequence due to two Lys residues. For both doubly- and
triply-charged peptide ions, HNCO loss is still promi-
nent from both precursor ions and several intense b
ions. The doubly-charged peptide showed HNCO loss
and some peptide bond cleavage ions, including b2, b3,
b7, b8, and b12 ions. The triply-charged peptide showed
more peptide cleavage products, explained by the in-
creased availability of mobile protons. These results
suggest that HNCO elimination competes with back-
bone cleavage and readily occurs in both proton-mobile
and fixed sequences.
We next tested whether the diagnostic HNCO could
be used to identify an unknown citrullination site.
Nucleophosmin (NPM) is a molecular chaperon in-
volved in nucleosome core particle assembling [27]. It
was shown previously that calcium ionophore triggers
PAD4 dependent citrullination of NPM in HL-60 gran-
ulocytes [15], but the exact site was unidentified. In
attempt to identify this citrullination site, we treated
recombinant human His6-NPM with GST-PAD4 and
analyzed the resulting deimination product. As shown
in Supplement Figure 3a, PAD4 treatment leads to
marked increase in citrulline level, as detected by
anti-Cit Western blotting. The gel band was excised,
subjected to trypsinolysis, resulting His6-NPM peptides
(with and without PAD4 pretreatment) were analyzedby LC-MS and database searching. The total ion chro-
matograms (TIC) of tryptic digests of PAD4 treated and
control NPM bands were shown in left panel of Figure
1a. The sequence coverage of database searching was
greater than 95% (Supplemental Figure 3b). The CID
spectra were extracted for the neutral losses of 43 and
21.5 Da. The neutral loss chromatogram of 43 Da was
shown in the right panel of Figure 1a. A single promi-
nent peak eluted around 12 min was detected in the
neutral loss chromatogram of 43 Da for PAD4-treated
band. The peak was derived from a singly-charged
peptide ion with m/z of 888.4 corresponding to tryptic
peptide SI{Cit}DTPAK containing citrullinated Arg197.
A similar result was obtained from neutral loss chro-
matogram of 21.5 Da, which revealed a doubly-charged
ion at m/z 444.7 of the same peptide (data not shown).
The CID spectra evidence HNCO loss from both the
singly- and doubly-protonated peptides (see Figure 1b).
The CID spectra of the unmodified peptide SIRDTPAK
were acquired under the same collision energy (Figure
1c). In contrast to the citrullinated species, only NH3
loss from the precursor was observed. Intriguingly, the
identified citrullination site is located in the vicinity of
the ribonuclease activity center [28], suggesting a po-
tential role for citrullination in the regulation of RNA-
substrate binding.
Conclusions
In summary, we demonstrate for the first time that
gas-phase elimination of HNCO is an abundant feature
of citrullinated peptides. The elimination occurs in both
proton mobile and sequestered peptide precursor ions.
Note that the Q Trap CID data resemble a quadrupole
instrument as it is carried out in the collision cell and
this dissociation was also prominently observed using
an ion trap instrument (data not shown). The neutral
loss should allow for post-acquisition searching of
MS/MS data to discover novel citrullination sites. The
incorporation of the side-chain loss into current search
engines would increase the confidence of spectra
matching and reduce the occurrence of false positive
identifications. The technical advance should enable a
more comprehensive identification of protein citrullina-
tion sites and aid in defining the roles of protein
citrullination in health and disease.
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